ArticleFrontiers in neurology2026
Case Report: Hereditary transthyretin amyloidosis in a Chinese family with the transthyretin variant p.Y89H.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hereditary transthyretin amyloidosis (hATTR) is a rare, life-threatening multisystem disorder caused by pathogenic variants in the transthyretin (TTR) gene. Its clinical manifestations are highly heterogeneous, frequently resulting in diagnostic delay or misdiagnosis.hATTR caused by the TTR p.Y89H variant is extremely rare and is associated with a phenotype characterized by predominant ocular and leptomeningeal involvement. Case presentation: A 59-year-old woman presented with a 10-year history of episodic headaches and a 3-year history of progressive bilateral visual decline. Brain computed tomography (CT) showed persistent diffuse leptomeningeal hyperdensities, and contrast-enhanced magnetic resonance imaging (MRI) revealed extensive, homogeneous enhancement of the cerebral and spinal leptomeninges. Genetic testing identified a heterozygous TTR variant, c.265 T > C (p.Y89H), in both the patient and her younger brother. The patient underwent left vitrectomy for vitreous opacities and received symptomatic treatment with ibuprofen for episodic headaches. Visual acuity in the left eye improved after vitrectomy, whereas visual acuity in the right eye continued to decline progressively during follow-up. CT obtained at one-year follow-up showed persistent leptomeningeal hyperdensities. Conclusion: In the appropriate clinical and genetic context, persistent leptomeningeal hyperdensities on brain CT may serve as a diagnostic clue for p.Y89H-associated hATTR, although this finding should be interpreted cautiously and differentiated from other leptomeningeal pathologies. Patients with leptomeningeal hATTR may also be susceptible to contrast-induced encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.